Market Research Logo

Pharmaceuticals in Scandinavia

Pharmaceuticals in Scandinavia

Summary

Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Scandinavia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
  • The Scandinavian pharmaceuticals market had total revenues of $12.8bn in 2017, representing a compound annual rate of change (CARC) of -0.7% between 2013 and 2017.
  • Although there is an ageing population which has driven the demand for drugs in Scandinavia, the market has declined due to the prevalence of generics.
  • The four Scandinavian component countries are heavily driven by a large government public health market and they have been affected by the trend of western governments to cutting down on pharmaceutical spending, instead trying to encourage greater adoption of generics and cheaper alternatives
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Scandinavia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia
  • Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts
Reasons to buy
  • What was the size of the Scandinavia pharmaceuticals market by value in 2017?
  • What will be the size of the Scandinavia pharmaceuticals market in 2022?
  • What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitiors in Scandinavia's pharmaceuticals market?


Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Novartis AG
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sanofi SA
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2013-17
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2017
Table 3: Scandinavia pharmaceuticals market share: % share, by value, 2017
Table 4: Scandinavia pharmaceuticals market value forecast: $ billion, 2017-22
Table 5: Novartis AG: key facts
Table 6: Novartis AG: key financials ($)
Table 7: Novartis AG: key financial ratios
Table 8: Pfizer Inc.: key facts
Table 9: Pfizer Inc.: key financials ($)
Table 10: Pfizer Inc.: key financial ratios
Table 11: F. Hoffmann-La Roche Ltd: key facts
Table 12: F. Hoffmann-La Roche Ltd: key financials ($)
Table 13: F. Hoffmann-La Roche Ltd: key financials (CHF)
Table 14: F. Hoffmann-La Roche Ltd: key financial ratios
Table 15: Sanofi SA: key facts
Table 16: Sanofi SA: key financials ($)
Table 17: Sanofi SA: key financials (€)
Table 18: Sanofi SA: key financial ratios
List of Figures
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2013-17
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2017
Figure 3: Scandinavia pharmaceuticals market share: % share, by value, 2017
Figure 4: Scandinavia pharmaceuticals market value forecast: $ billion, 2017-22
Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2017
Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2017
Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2017
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2017
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2017
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2017
Figure 11: Novartis AG: revenues & profitability
Figure 12: Novartis AG: assets & liabilities
Figure 13: Pfizer Inc.: revenues & profitability
Figure 14: Pfizer Inc.: assets & liabilities
Figure 15: F. Hoffmann-La Roche Ltd: revenues & profitability
Figure 16: F. Hoffmann-La Roche Ltd: assets & liabilities
Figure 17: Sanofi SA: revenues & profitability
Figure 18: Sanofi SA: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report